

Wednesday, January 23, 2008

COMPANY PRESS RELEASE

Transgenomic Appoints Dr. Eric Kaldjian as Chief Scientific Officer

Brings extensive Cancer research expertise and Pharmaceutical Industry experience

OMAHA, Neb., January 23, 2008 – Transgenomic, Inc. (OTCBB: TBIO.OB), today announced that Eric Kaldjian, M.D. has joined its executive management team as Chief Scientific Officer. Dr. Kaldjian will lead the Company's research and development and biomarker development efforts and serve as a clinical medicine resource.

Before joining Transgenomic, Dr. Kaldjian served as Executive Director, Medical Sciences at Gene Logic, Inc, directing programs that included clinical genomics, biomarkers and molecular diagnostics development. He also functioned as principle investigator in research collaborations and developed strategic partnerships with clinical and pre-clinical investigations. Prior to this, he was Exploratory Therapeutic Area Leader, Oncology and Experimental Medicine for Pfizer Global Research & Development. He also served as an Associate Research Fellow, Diagnostic Pathology, for Parke-Davis Pharmaceutical Research and Associate Clinical Director with Hoffmann-La Roche in oncology and transplant programs.

Craig Tuttle, Transgenomic President and Chief Executive Officer, commented, "Eric brings a unique expertise in the pathobiology and genomics of cancer and other diseases. In addition, his work at Gene Logic included extensive collaborative research and microarray-based gene expression analysis. Eric has had clinical drug development experience with several major pharmaceutical companies, clinical diagnostic experience at the National Cancer Institute, and was an adjunct professor at the University of Michigan Medical School. His publications include papers in clinical trials, biomarkers, cancer, immunology and genomics. We are excited to bring his leadership to our R&D efforts, where he will develop and lead collaborations with leading researchers, particularly cancer researchers, worldwide to facilitate our mutation discovery efforts and support continued growth of our clinical and pharmacogenetic laboratories offerings."

Dr. Kaldjian earned his MD at the University of Michigan Medical School and graduated *cum laude* from Harvard College with a Bachelor of Arts degree in chemistry. He received his residency training in pathology at the University of Michigan Medical Center before his fellowship training in Lymphoid Pathology and Research at the National Cancer Institute, NIH. He holds a State of Michigan Board of Medicine Physician License and is a diplomate in Anatomic Pathology from the American Board of Pathology.

About Transgenomic:

Transgenomic is a global biotechnology company that provides unique products and services of automated high sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Specific offerings include WAVE® DHPLC Systems, related consumables and assay kits, cytogenetics automated systems, and Transgenomic Discovery and CLIA Lab Services.

Transgenomic Discovery and Lab Services utilize their technology and expertise to provide a menu of mutation scanning tests for over 700 cancer-associated genes and more than 60 validated diagnostic tests to meet the needs of pharmaceutical and biotech companies, research and clinical laboratories, physicians and patients. For more information about the innovative systems, products and services offered by Transgenomic, please visit: www.transgenomic.com.

Deb Schneider
Chief Financial Officer
Transgenomic, Inc.
(402) 452-5446
dwschneider@transgenomic.com

Todd Kehrli or Jim Byers
Investor Relations
MKR Group, Inc.
(323) 468-2300
tbio@mkr-group.com